Financing of Curative Cell, Gene Therapies and Variability W

While the novel payment models for expensive cell and gene therapies have been effective, they need to continue evolving, said Joe DePinto, MBA, of McKesson.

Related Keywords

United States , Nevada , American , Joe Depinto , Eddie Albers , Emad Samad , Las Vegas , Reuters , Health Aff Millwood , Mckesson , Us Life Sciences Practice Leader , Epharmacy Summit , Sciences Practice Leader , Octaviant Financial , American Journal , Cell And Gene Therapies , Value Based Payment ,